共 393 条
[61]
Nakano A(2001)Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2 Curr Treat Options Oncol 2 271-1228
[62]
Cackowski FC(2006)Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation Clin Cancer Res 12 1221-1639
[63]
Roodman GD(2007)Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis Blood 118 1054A-1782
[64]
Hsu H(2006)Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group Eur J Cancer 42 1623-73
[65]
Lacey DL(2003)Bone disease in myeloma J Clin Invest 111 1771-238
[66]
Dunstan CR(2005)A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer Br J Haematol 131 71-1467
[67]
Solovyev I(2006)An open label phase 2 trial of Denosumab in the treatment of relapsed or plateau-phase myeloma Eur J Haematol 77 233-338
[68]
Colombero A(2003)Proteasome inhibition in multiple myeloma Leuk Lymphoma 44 1463-438
[69]
Timms E(2007)Selective inhibitors of the osteoblast proteasome stimulate bone formation Blood 110 334-692
[70]
Nakagawa N(2007) and Br J Haematol 139 434-1622